Activation of JAK2-V617F by Components of Heterodimeric Cytokine ReceptorsAnuradha Pradhan(Molecular Oncology (United States)), Gary W. Reuther(Moffitt Cancer Center)Journal of Biological ChemistryApril 7, 201010.1074/jbc.m109.071191Cited by 30SaveCiteExport RISWatch citationsRelated PapersALK-Activating Homologous Mutations in LTK Induce Cellular Transformation|PLoS ONE|2012|39The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells|Oncotarget|2015|38<scp>SHP2</scp> inhibition displays efficacy as a monotherapy and in combination with <scp>JAK2</scp> inhibition in preclinical models of myeloproliferative neoplasms|American Journal of Hematology|2024|4